Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

Por Smith, Catherine C., Lasater, Elisabeth A., Zhu, Xiaotian, Lin, Kimberly C., Stewart, Whitney K., Damon, Lauren E., Salerno, Sara, Shah, Neil P.
Publicado em 2013

Crenolanib is a selective type I pan-FLT3 inhibitor

Por Smith, Catherine Choy, Lasater, Elisabeth A., Lin, Kimberly C., Wang, Qi, McCreery, Melissa Quino, Stewart, Whitney K., Damon, Lauren E., Perl, Alexander E., Jeschke, Grace R., Sugita, Mayumi, Carroll, Martin, Kogan, Scott C., Kuriyan, John, Shah, Neil P.
Publicado em 2014

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

Por Smith, Catherine C., Wang, Qi, Chin, Chen-Shan, Salerno, Sara, Damon, Lauren E., Levis, Mark J., Perl, Alexander E., Travers, Kevin J., Wang, Susana, Hunt, Jeremy P., Zarrinkar, Patrick P., Schadt, Eric E., Kasarskis, Andrew, Kuriyan, John, Shah, Neil P.
Publicado em 2012

Characterizing and Overriding the Structural Mechanism of the Quizartinib-resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397

Por Smith, Catherine C., Zhang, Chao, Lin, Kimberly, Lasater, Elisabeth A., Zhang, Ying, Massi, Evan, Damon, Lauren E., Pendleton, Matthew, Bashir, Ali, Sebra, Robert, Perl, Alexander, Kasarskis, Andrew, Shellooe, Rafe, Tsang, Garson, Carias, Heidi, Powell, Ben, Burton, Elizabeth A., Matusow, Bernice, Zhang, Jiazhong, Spevak, Wayne, Ibrahim, Prabha N., Le, Mai H., Hsu, Henry H., Habets, Gaston, West, Brian L., Bollag, Gideon, Shah, Neil P.
Publicado no Cancer Discov (2015)